LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Kymera Therapeutics Inc

Ouvert

SecteurSoins de santé

87 1.03

Résumé

Variation du prix de l'action

24h

Actuel

Min

83.94

Max

87.81

Chiffres clés

By Trading Economics

Revenu

18M

-69M

Ventes

32M

34M

BPA

-0.71

Marge bénéficiaire

-201.467

Employés

253

EBITDA

18M

-67M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+37.02% upside

Dividendes

By Acuity

Prochains Résultats

11 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-979M

6.1B

Ouverture précédente

85.97

Clôture précédente

87

Sentiment de l'Actualité

By Acuity

50%

50%

146 / 342 Classement par Healthcare

Kymera Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

À Propos Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat